M ultiple sclerosis (MS)
is an inflammatory demyelinating disorder of the CNS that affects 2.5 million people worldwide and represents the leading cause of neurologic disability in the young adult population (1) . In MS, myelinreactive CD4 + Th1 and Th17 cells are generally believed to drive an immune-mediated attack against components of the myelin sheath, leading to demyelination and axonal damage (2) . However, the pathologic mechanisms underlying the development of MS are still incompletely understood.
In recent years, several pieces of evidence have suggested that sex-related factors might influence both incidence and progression of MS (3) . Epidemiologic studies have shown that MS affects more frequently women than men, with a female/male ratio ranging from 2:1 to 3:1, depending on geographic areas (3) . Pregnancy also importantly affects the clinical course of MS. Relapse rate significantly declines during the third trimester of pregnancy but considerably increases in the first 3 mo after delivery, if compared with prepregnancy rates (4, 5) . Similarly to human disease, pregnancy suppresses clinical symptoms of experimental autoimmune encephalomyelitis (EAE), an animal model for MS (6, 7) , and induction of chronic EAE in the postpartum period results in enhanced mortality and slightly worsened severity (7) . Among sexrelated factors, hormones have been hypothesized to play an important role in regulating MS and EAE (3) . Prolactin (PRL) is a 199-aa peptide hormone mainly secreted by lactotrophic cells of the anterior pituitary gland and by other sources including immune cells (8) . The best established functions of PRL are related to mammary gland development and regulation of lactation and female reproduction (9) . Mean PRL serum levels are slightly but significantly higher in women (∼2-20 mg/l) than in men (∼2-10 mg/l) (10) . PRL secretion increases during pregnancy and peaks postpartum in association with breastfeeding. In parallel to its reproductive functions, a large body of literature has argued for a role of PRL in the regulation of both cell-mediated and humoral immune responses (11) (12) (13) . PRL binds to a single-pass transmembrane receptor (PRLR), belonging to the class I cytokine receptor superfamily, which includes receptors for IL-2, IL-6, GM-CSF, and leptin (8) . In vitro studies have shown that PRL sustains survival, proliferation, and differentiation of T cell precursors (14) , and modulates CD4 + T cell expression of T-bet, a key transcription factor for the differentiation of Th1 cells (15) . PRL has also been reported to stimulate the maturation of monocyte-derived dendritic cells (16) . In mouse models of systemic lupus erythematosus (SLE), a multiorgan Ab-dependent autoimmune disease, PRL administration increases autoreactive immune responses (17, 18) , by breaking B cell tolerance and enhancing titers of autoreactive Abs (18) . In human SLE, higher serum levels of PRL correlate with greater disease severity, and treatment of SLE patients with bromocriptine (BCR), a dopamine D2 agonist that inhibits PRL secretion, reduces disease activity (19) .
In MS, hyperprolactinemia has been largely debated (20) . Early studies in rat EAE showed that serum PRL levels increase during the induction phase of disease (21) , and treatment with BCR improves clinical signs of EAE (21, 22) , suggesting a detrimental role for PRL in EAE. However, stimulation of D2 dopaminergic receptors on immune cells can modulate their functions, and BCR has been shown to directly suppress human T cell proliferation independently of PRL (23) . Moreover, BCR might not allow a complete depletion of PRL, as other extrapituitary sites of PRL secretion have been suggested (9) . Given these limitations, a clear indication about the role of PRL in MS and EAE is still lacking.
In this study, using two mouse models with gene-targeted deletions of either PRL receptor (Prlr and Prl +/+ as recommended by the vendor. C57BL/6 mice were from Charles River. Mice were bred and maintained under pathogen-free conditions at the animal facility of the Foundation IRCCS Neurological Institute Carlo Besta. Age-matched female 8-to 12-wk-old mice were used in all EAE experiments. Both knockout strains bear an H-2b haplotype, which confers susceptibility to MOG -induced EAE. However, Prl 2/2 mice were backcrossed into C57BL/6 background, which is known to be more susceptible to EAE development than the 129 background, into which Prlr 2/2 mice were backcrossed (26, 27) . All procedures involving animals were approved by the Institute Ethical Committee and performed in accordance to institutional guidelines and national law (DL116/92), and carried out according to the Principles of Laboratory Animal Care (European Communities Council Directive 86/609/EEC).
Peptide synthesis and EAE induction
MOG (MEVGWYRSPFSRVVHLYRNGK) and control peptide (rat P0; DGDFAIVKFTKVLLDYTGHI) were synthesized using a standard 9-fluorenylmethoxycarbonyl chemistry on a 433A automated peptide synthesizer (Applied Biosystems) and purified by HPLC. The purity of each peptide was .95% as assessed by analytical reverse-phase HPLC. EAE was induced as previously described (28) . In brief, MOG peptide was dissolved in PBS to a concentration of 2 mg/ml and emulsified with an equal volume of IFA supplemented with 8 mg/ml heat-killed Mycobacterium tuberculosis H37Ra (Difco). Mice were injected s.c. in their flanks with 0.1 ml of the peptide emulsion (for a total of 100 mg MOG and 400 mg M. tuberculosis/mouse) and, on the same day and 48 h later, were injected i.v. with 0.2 ml containing 200 ng Bordetella pertussis toxin (List Laboratories) dissolved in PBS. Mice were assessed daily for neurologic signs of EAE according to the following five-point scale: 0, healthy; 1, tail weakness or paralysis; 2, paraparesis (incomplete paralysis of one or two hind limbs/plegia of one hind limb); 3, paraplegia extending to the thoracic level; 4, forelimb weakness or paralysis with hind limbs paraparesis or paraplegia; and 5, moribund or dead animal.
T cell activation assay and cytokine analysis
Draining LN cells (LNCs) were isolated from immunized mice 7-10 d after EAE induction and cultured in vitro with MOG , Con A (1 mg/ml; positive control), rat P0 (negative control), or medium alone. Cells were cultured in 96-well U-bottom plates at a density of 2 3 10 5 cells/well in 200 ml RPMI 1640 (EuroClone) supplemented with L-glutamine (2 mM), sodium pyruvate (1 mM), nonessential amino acids (0.1 mM), penicillin (100 U/ml), streptomycin (0.1 mg/ml), HEPES buffer (0.01 M), and 10% FCS (enriched RPMI 1640). After 48 h of incubation at 37˚C with 5% CO 2 , cultures were pulsed with 0.5 mCi [
3 H]thymidine per well for 18 h, and proliferation was measured from triplicate cultures on a beta counter (PerkinElmer). Supernatants from parallel cultures were tested for production of IFN-g, IL-6, IL-10 (anti-mouse OptEIA ELISA Set; BD Pharmingen), and IL-17A (Mouse IL-17 Duoset; R&D Systems) by ELISA, according to manufacturer's protocols. Results are shown as mean of duplicates; SEM were always within 10% of the mean. Untouched CD4 + T cells were magnetically purified by negative selection from suspensions of splenocytes from naive C57BL/6 mice according to manufacturer's protocol (CD4 + T cell Isolation Kit II; Miltenyi). Cell purity (.95%) was confirmed by flow cytometry. CD4 + T cells (2 3 10 5 cells/well) were cultured in 96-well plates in 200 ml enriched RPMI 1640 with anti-CD3 (1 mg/ml) and anti-CD28 (5 mg/ml) Abs (BD Pharmingen) or medium alone and harvested after 48 h at 37˚C with 5% CO 2 for gene expression analysis of Prl and Prlr, and measurement of PRL in supernatants.
Measurement of MOG 35-55 -specific IgG response
Blood was collected from the tail vein of immunized mice before and 5 wk after the induction of EAE. MOG -specific IgG, IgG1, IgG2a, IgG2b, and IgG3 Abs were measured by ELISA as described elsewhere (28) . In brief, 96-well plates (Immunol; Thermo Labsystems) were coated overnight at 4˚C with 0.1 ml MOG 35-55 diluted in 0.1 M NaHCO 3 buffer (pH 9.5) at a concentration of 0.010 mg/ml. The plates were blocked with PBS/ 10% FCS (blocking buffer) for 2 h. Samples were diluted in blocking buffer at 1/100, and Ab binding was tested by the addition of peroxidaseconjugated monoclonal goat anti-mouse IgG, IgG1, IgG2a, IgG2b, and IgG3 (Southern Biotechnology Associates), each at a 1:5000 dilution in blocking buffer. Enzyme substrate was added, and plates were read at 450 nm on a microplate reader. (29) . Prlr primer pairs have been designed to amplify exons 4-5, which are common to the four described isoforms of PRLR. Expression of target genes was quantified by the comparative threshold cycle method, and Gapdh was used as housekeeping gene. Data are presented as percentage of the housekeeping gene Gapdh 6 SD.
Real-time PCR

Measurement of PRL in supernatants and sera
PRL was measured in supernatants of cultured CD4 + T cells and sera of naive or immunized C57BL/6 mice by ELISA (Mouse Prolactin Duoset; R&D Systems), according to manufacturer's instructions. Serum PRL concentrations were tested during priming (i.e., day 7 p.i.), onset, and acute phases of MOG 35-55 -induced EAE. Sera collected from naive Prlr 2/2 mice, which display hyperprolactinemia (9), and naive Prl 2/2 mice were used as positive and negative controls, respectively.
Statistical analysis
For clinical data, Mann-Whitney U test was used to compare results between two groups. For all other analyses, unpaired Student t test, two tailed, was used to compare results between two groups. Analysis was performed by SPSS software. In all tests, *p , 0.05 was considered statistically significant. mice during the priming phase of EAE, and examined in vitro the proliferative recall response and cytokine production in response to MOG (18) . We therefore evaluated in our models whether PRL had any impact on the production of autoreactive IgG Abs. We did not find significant differences in titers of IgG specific for MOG in sera from immunized Prlr 2/2 , Prl 2/2 , and their respective control mice (Fig. 4A, 4B ). Table I . Data are pooled from two independent consecutive experiments that gave similar results, each including 6-15 mice/group.
Results
EAE
with MOG and measured serum PRL concentrations. In contrast with a previous study reporting an increase in serum PRL levels in rat EAE (21), we observed a reduction of serum PRL concentrations in mice with EAE compared with naive mice (Fig. 5) . Although PRL is mainly secreted centrally by the pituitary, PRL has been suggested to be secreted also peripherally in lymphoid organs (30) . However, previous work has failed to detect mRNA for Prl in mouse spleen, thymus, LN, and bone marrow (31) . More recent work reported Prl mRNA expression in mouse thymocytes and in freshly isolated or mitogen-stimulated splenocytes (30) . Moreover, immunoreactivity for PRL in some splenic CD4 + T cells has been described (32) , although this work did not clarify whether CD4 + cells were the sources of PRL or were binding PRL deriving from other sources. To evaluate any possible contribution of PRL produced and secreted locally in secondary lymphoid organs to the development of autoreactive T cell responses, we first harvested LNs from naive C57BL/6 mice (H2b haplotype) and assessed ex vivo by real-time PCR the expression of Prl transcript in total LNCs and in magnetically purified CD4 + T cells. We did not find expression of Prl mRNA in either LNCs or CD4 + T cells of these mice (Fig. 6A) . Next, to evaluate the possibility that the transcription of Prl gene is induced in immune cells during EAE, we repeated the analysis in LNCs and purified CD4 + T cells harvested from C57BL/6 mice during the priming phase of MOG 35-55 -induced EAE. We failed to detect Prl transcript also in these in vivo activated cells (Fig.  6A) . To further test the hypothesis of an induction of Prl gene transcription upon immune stimulation, we activated in vitro CD4 + T cells purified from naive C57BL/6 mice with anti-CD3 and anti-CD28 Abs, and analyzed mRNA expression of Prl by real-time PCR and PRL protein secretion in culture supernatants by ELISA. PRL was undetectable at both transcript (Fig. 6C ) and protein levels (data not shown) also after stimulation. These data are consistent with results reported by Clevenger and colleagues (33) showing that a murine Th cell line, either resting or stimulated with IL-2 or Con A, does not express PRL at either mRNA or protein level. Taken together, our findings indicate that PRL concentrations do not increase during EAE, and that neither T cells nor LNCs express and secrete PRL, thus ruling out CD4 + T cells as a possible source of local PRL that could contribute to the development of autoreactive T cell responses in EAE. Conversely, in line with previous findings (8), we found expression of Prlr mRNA in both LNCs and purified CD4 + T cells isolated from C57BL/6 naive mice or mice with EAE. Interestingly, we observed a reduction of Prlr transcript during the priming phase of EAE (Fig. 6B) . CD4 + T cells activated in vitro with anti-CD3 and anti-CD28 Abs displayed a downregulation of Prlr mRNA 48 h after stimulation in comparison with unstimulated cells (Fig. 6C) . It must be taken into consideration that expression of Prlr gene at the mRNA level might be different from that of PRLR at the protein level, because of complex regulatory processes controlling the final expression of protein in a cell. Nevertheless, given the observed downregulation of Prlr mRNA in CD4 + T cells after in vitro stimulation, it is possible that downregulation of Prlr transcript in mice immunized for EAE reflects the activation state of CD4 + T cells during the disease.
Discussion
Collectively, this study provides evidence that PRL plays a redundant role in the development of chronic EAE, and that PRL locally produced in lymphoid organs is unlikely to exert an immune-modulating effect on immune cells during EAE in this model. Even though we observed a delay in the onset of EAE symptoms, which was associated with a delay in the establishment of anti-MOG peptide Th1 and Th17 responses in LNs, the overall severity of EAE was indistinguishable between mice have normal myelopoiesis and primary lymphopoiesis (25) . Our findings are consistent with the study of Bouchard and colleagues (34) showing that Prlr 2/2 mice mount an effective immune response to several types of stimuli, such as infection with an intracellular pathogen (i.e., Listeria monocytogenes) and injection with an allogeneic tumor cell line. In this work, it was also demonstrated that Prlr 2/2 mice develop a normal specific Ig response after immunization with a non-self Ag (34) . In line with these results, we show that IgG response against the self-Ag MOG was not affected by PRLR or PRL deficiency. In the MS field, PRL has gained renewed interest in recent years, because two studies showed that exclusive breastfeeding (a hyperprolactinemic physiologic condition) reduces the risk for postpartum relapses (35, 36) , albeit other articles reported discordant results (5, 37, 38) . Further, another article has demonstrated that PRL mediates proliferation of oligodendrocyte progenitor cells during pregnancy and promotes myelin repair in a spontaneously remyelinating model of chemical (lysolecithin)-induced focal demyelination, suggesting PRL as a potential therapeutic agent for MS (39) . By studying EAE, an immune-mediated model of demyelination, in PRLR-and PRL-deficient mice, we had the possibility to evaluate the net effect of PRL on disease development between the potential immune-stimulating (detrimental) and myelinogenic (beneficial) properties of this hormone. Our data indicate that physiologic levels of PRL do not impact crucially on the clinical course of chronic EAE and on autoreactive immune response against myelin underlying the disease. Moreover, we did not observe in absence of PRL or PRLR a worsening of EAE severity, which could have been expected in the hypothesis of a key role for PRL in myelin repair. However, the robustness of the EAE model and the severe clinical phenotype developed by PRLdeficient, PRLR-deficient, and control mice might have well masked possible clinical effects related to the lack of PRL or PRLR in disease recovery. Lastly, we cannot rule out that a physiopathologic or pharmacologically induced hyperprolactinemic state might impact more importantly on EAE and on self-reactive T cell responses. In fact, pregnancy and breastfeeding are characterized by high hyperprolactinemia (∼100-800 ng/ml), and by several other physiologic adaptations, which further complicate the interpretation of the possible role of PRL on disease activity. Thus, further investigation is required to understand whether hyperprolactinemia of pregnancy and breastfeeding has any effect on the development and progression of EAE and MS.
